Lung Cancer

FDA Approves Selpercatinib for RET+ Lung and Thyroid Cancers

May 09, 2020

The FDA has approved selpercatinib capsules for the treatment of patients with lung cancer or thyroid cancer harboring RET alterations. This marks the first treatment approved to target RET gene alterations.

Capmatinib Companion Diagnostic Approved by FDA for MET-Positive NSCLC

May 08, 2020

"This simultaneous therapy and companion diagnostic approval marks an important step forward in the treatment of rare cancer and demonstrates how deep collaboration across industry partners can advance patient care.”

Canakinumab Plus Pembrolizumab and Chemotherapy Appears Safe in Advanced NSCLC

May 07, 2020

Based on these findings, the 200 mg dose of canakinumab administered subcutaneously every 3 weeks in combination with the standard dose of pembrolizumab and a platinum-based chemotherapy doublet will be used in the next phase of the CANOPY-1 study.

Sintilimab Shows Progression-Free Survival Benefit in Front-line NSCLC

May 07, 2020

"The emergence of the anti-PD-1 antibody has brought a new treatment modality for patients with squamous NSCLC."

FDA Approves Capmatinib in MET Exon 14+ Metastatic Non-Small Cell Lung Cancer

May 06, 2020

“We are pleased that the FDA has approved Tabrecta for patients with METex14 NSCLC. Having a therapy that targets the recognized oncogenic driver will provide a much needed treatment option for patients with METex14 NSCLC who currently have limited treatment options.”

Molecular Testing Used for Patients With Non-Small Cell Lung Cancer

May 05, 2020

Rogerio C. Lilenbaum, MD, discusses molecular panels and other testing for patients with nonsquamous non-small cell lung cancer.

FDA Approves Pembrolizumab Companion Diagnostic for Frontline PD-L1+ NSCLC

April 23, 2020

"We are delighted to add the first FDA approval of this important companion diagnostic on Dako Omnis."

Doctors Debate: Should Immunotherapy Be Given Before or After Surgical Resection in Locally Advanced NSCLC?

April 22, 2020

“We don’t have a good understanding of why some patients have a robust response to immunotherapy and others do not. That’s important, not only in terms of selecting patients but also in terms of the therapy approach. This is one reason why clinical trials are incredibly important.”

Nivolumab/Ipilimumab Combo Improves OS in Malignant Pleural Mesothelioma

April 20, 2020

“These topline results from the CheckMate 743 trial demonstrate the potential of Opdivo plus Yervoy in previously untreated patients with malignant pleural mesothelioma, and is another example of the established efficacy and safety of the dual immunotherapy combination seen in multiple tumor types.”

Aggarwal Reviews the Latest Data Related to Systemic Therapy in Stage III NSCLC

April 19, 2020

In a Targeted Oncology case-based peer perspectives live discussion, Charu Aggarwal, MD, MPH, discussed systemic treatment options for stage III non–small cell lung cancer, based on a real case of a 63-year-old male patient.